University of Pittsburgh

Novartis Ag

University of Pennsylvania

Avigen, Inc.

Intrexon Corporation

Hideho Okada

Walter J Storkus

Carl H June

Andreas Loew

Jennifer Brogdon

Marcela V Maus

John Scholler

Laura Alexandra Johnson

Peter C Colosi

Gary J Kurtzman

Jun Yoshida

Masaaki Mizuno

J Mark Braughler

Prasanna Kumar

Gary Kohanbash

Kotaro Sasaki

Junichi Eguchi

Hidemitsu Sato

Mark Braughler

The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.

Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor

The invention provides a peptide derived from the interleukin-13 receptor &#x3b1;2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. In addition, the invention provides the use of a peptide derived from the Eph family of tyrosine kinase receptors which can be also used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use.

Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response

Provided herein are interleukin-13 receptor &#x3b1;2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor &#x3b1;2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor &#x3b1;2 peptides and at least one additional peptide and/or immunostimulant.

Methods for treating brain cancer using il-13r alpha 2 peptide-based compositions

This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.

Engineered dendritic cells and uses for the treatment of cancer

Described herein is the identification of miRNAs (miRs) that are up-regulated in Th1 cells compared to Th2 cells (referred to herein as Th1-associated miRs). In particular, the miR-17-92 gene cluster was found to exhibit significantly greater expression in Th1 cells. Over-expression of miR-17-92 in T cells promotes the Th1 phenotype. Thus, the use of Th1-associated miRs for cancer immunotherapy is described. Provided herein are isolated T cells containing a heterologous nucleic acid molecule encoding a Th1-associated miR, such as the miR17-92 gene cluster, or a portion thereof. Further provided is a method of treating cancer in a subject by administering to the subject an isolated T cell as disclosed herein. Also provided is a method of treating a subject with cancer by transfecting isolated T cells obtained from the subject with a heterologous nucleic acid molecule encoding a Th1-associated miR and administering the transfected T cells to the subject.

Th1-associated microRNAs and their use for tumor immunotherapy

The use of recombinant adeno-associated virus (AAV) virions for the treatment of solid tumors is disclosed. The invention provides for the use of recombinant AAV virions to deliver an AAV vector containing a drug-susceptibility gene and a second gene capable of providing an ancillary effect to solid tumor cells. The second gene can be used to enhance the immunogenicity of the transduced tumor cell. Alternatively, the second gene can be used to provide a tumorstatic effect. The invention also provides for the use of recombinant AAV virions to deliver an interferon gene, or a tumor suppressor gene to provide a therapeutic effect in a transduced tumor cell.

Gene therapy for the treatment of solid tumors using recombinant adeno-associated virus vectors

Adeno-associated virus vectors comprising a first and second nucleic

Growing community of inventors

Pittsburgh, PA, United States of America

Hideho Okada